86,420 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Renaissance Technologies LLC

Renaissance Technologies LLC acquired a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 86,420 shares of the company's stock, valued at approximately $5,479,000. Renaissance Technologies LLC owned 0.29% of Disc Medicine as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IRON. FMR LLC lifted its holdings in shares of Disc Medicine by 358.7% during the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after buying an additional 1,459,434 shares during the period. Vanguard Group Inc. increased its position in Disc Medicine by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company's stock valued at $67,727,000 after acquiring an additional 18,716 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Disc Medicine by 17.6% in the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock valued at $23,333,000 after acquiring an additional 70,983 shares during the period. Victory Capital Management Inc. boosted its position in Disc Medicine by 7.4% in the fourth quarter. Victory Capital Management Inc. now owns 236,244 shares of the company's stock worth $14,978,000 after purchasing an additional 16,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Disc Medicine by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 165,072 shares of the company's stock valued at $10,466,000 after purchasing an additional 4,518 shares during the period. Hedge funds and other institutional investors own 83.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on IRON. Wedbush reissued an "outperform" rating and issued a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley reiterated an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. Stifel Nicolaus upped their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. TD Cowen initiated coverage on Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Disc Medicine currently has an average rating of "Buy" and an average target price of $93.80.

Insider Transactions at Disc Medicine

In other news, CFO Jean M. Franchi sold 3,136 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,162.88. Following the sale, the chief financial officer now directly owns 69,530 shares in the company, valued at approximately $3,794,947.40. This represents a 4.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of Disc Medicine stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the completion of the transaction, the chief operating officer now owns 40,555 shares of the company's stock, valued at approximately $2,213,491.90. This represents a 3.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 361,690 shares of company stock valued at $19,648,094 in the last ninety days. Corporate insiders own 4.24% of the company's stock.

Disc Medicine Stock Down 0.4 %

NASDAQ IRON traded down $0.21 on Friday, reaching $45.97. The company had a trading volume of 57,984 shares, compared to its average volume of 344,558. The firm's 50 day moving average price is $48.73 and its 200 day moving average price is $55.04. Disc Medicine, Inc. has a 12 month low of $25.64 and a 12 month high of $68.73. The stock has a market capitalization of $1.59 billion, a PE ratio of -11.52 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. On average, research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.